Trial Profile

A Phase I Study of LX-039 Tablets in Postmenopausal Patients With ER+, HER2- Advanced Breast Cancer After Failure of Endocrine Therapy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LX 039 (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Adverse reactions; First in man
Sponsors Shandong Luoxin Pharmaceutical

Most Recent Events

24 Oct 2023 Results assessing the safety and efficacy of LX-039 in postmenopausal patients with ER+, HER2- advanced breast cancer patients, presented at the 48th European Society for Medical Oncology Congress.
23 Oct 2023 According to Luoxin Pharmaceutical media release, data from this study was selected for poster presentation at the 2023 ESMO Annual Congress.
23 Oct 2023 Results published in the Luoxin Pharmaceutical Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com